Press Releases

  • 2023 - 24

    SPARC to Present at the 42nd Annual J.P. Morgan Healthcare Conference

    SPARC enters into an exclusive worldwide license agreement for SCD-153 with JHU and IOCB

    SPARC Completes Enrolment in PROSEEK, A Global Phase 2 Study of Vodobatinib in Early Parkinson’s Disease

    SPARC to Provide Update on Clinical Programs and R&D Pipeline

    FDA issues complete response letter for PDP-716 NDA due to inspection findings at third-party API manufacturing facility

  • 2022 - 23

    SEZABY™ (phenobarbital sodium powder for injection) approved by US FDA for the treatment of neonatal seizures

    Sun Pharma and SPARC enter into a license agreement for commercialization of phenobarbital for injection in the US

    SPARC to Provide Update on Clinical Programs and R&D Pipeline

  • 2021 - 22

    SPARC to present updated clinical data of vodobatinib (SCO-088) at the 63rd ASH annual meeting

    SPARC Licenses Development and Commercialization Rights of PDP-716 and SDN-037 to Visiox Pharma

    SPARC enters into a licensing agreement with Biomodifying to acquire exclusive rights for antibody against unique oncology target

    SPARC to Provide Update on Clinical Programs and R&D Pipeline

    SPARC Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of PDP-716 for the Treatment of Open Angle Glaucoma or Ocular Hypertension

  • 2020 - 21

    SPARC Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of SDN-037 for the Treatment of Inflammation and Pain Associated with Ocular Surgery

    SPARC Licenses Commercialization Rights of ElepsiaTM XR to Tripoint Therapeutics

    SPARC to Provide Update on R&D Pipeline

    SPARC enters into a worldwide license agreement for SCD-044 with Sun Pharma

    SPARC to Provide Update on TaclantisTM NDA

  • 2019 - 20

    SPARC acquires Bioprojet’s rights for SCD-044

    SPARC Provides Update on Paclitaxel Injection Concentrate for Suspension (PICS) Litigation

    SPARC Enters into a Licensing Deal with CMS

    SPARC to Provide Update on R&D Pipeline

    SPARC Receives Orphan Drug Designation from the USFDA for SCO-088 for the Treatment of Patients with Chronic Myeloid Leukemia

    SPARC Announces U.S. FDA Acceptance of NDA for TaclantisTM (Paclitaxel Injection Concentrate for Suspension) for Filing and Regulatory Review

    HitGen and SPARC Enter DNA-Encoded Library Based Innovative Drug Discovery Research Collaboration

  • 2018 - 19

    Schrödinger and SPARC Announce Collaboration to Accelerate Neurodegeneration Drug Development Program

    SPARC Announces Top-line Results of Pivotal Bioequivalence Study for Paclitaxel Injection Concentrate for Suspension

    Sun Pharma and SPARC Announce US FDA Approval of XELPROS™ to Treat Open-angle Glaucoma or Ocular Hypertension

    Audio playback of Investors Presentation

    Update on R&D Pipeline

  • 2017 - 18

    SPARC Provides Update on Pivotal Phase III Studies of Baclofen GRS for Treatment of Spasticity in Patients with Multiple Sclerosis

    SPARC Announces Top-line Results of Pivotal Peak Inspiratory Flow (PIF) study and Low Dose Pharmacokinetic (PK) Study for Salmeterol – Fluticasone Dry Powder Inhaler (SPARC DPI)

  • 2016 - 17

    Announcement – Receipt of reclassification approval from BSE

    Announcement – Receipt of reclassification approval from NSE

    Update on NCE and NDDS Programs

    SPARC Licenses ELEPSIATM XR (Levetiracetam ER Tablets) to Sun Pharma

  • 2015 - 16

    Update on XELP ROST and Elepsia XRT

    SPARC Receives Complete Response Letter (CRL) from USFDA for Levetiracetam NDA

    SPARC Receives Complete Response Letter (CRL) from USFDA for Latanoprost NDA

    SPARC Licenses Xelpros™ to Sun Pharma

    SPARC receives USFDA approval for ELEPSIA XR

  • 2014 -15

    SPARC receives Complete Response Letter (CRL) from USFDA for Latanoprost NDA

    India Approval for Paclitaxel Injection Concentrate for Nanodispersion (PICN)

  • 2023 - 24

    SPARC to Present at the 42nd Annual J.P. Morgan Healthcare Conference

    SPARC enters into an exclusive worldwide license agreement for SCD-153 with JHU and IOCB

    SPARC Completes Enrolment in PROSEEK, A Global Phase 2 Study of Vodobatinib in Early Parkinson’s Disease

    SPARC to Provide Update on Clinical Programs and R&D Pipeline

    FDA issues complete response letter for PDP-716 NDA due to inspection findings at third-party API manufacturing facility

  • 2022 - 23

    SEZABY™ (phenobarbital sodium powder for injection) approved by US FDA for the treatment of neonatal seizures

    Sun Pharma and SPARC enter into a license agreement for commercialization of phenobarbital for injection in the US

    SPARC to Provide Update on Clinical Programs and R&D Pipeline

  • 2021 - 22

    SPARC to present updated clinical data of vodobatinib (SCO-088) at the 63rd ASH annual meeting

    SPARC Licenses Development and Commercialization Rights of PDP-716 and SDN-037 to Visiox Pharma

    SPARC enters into a licensing agreement with Biomodifying to acquire exclusive rights for antibody against unique oncology target

    SPARC to Provide Update on Clinical Programs and R&D Pipeline

    SPARC Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of PDP-716 for the Treatment of Open Angle Glaucoma or Ocular Hypertension

  • 2020 - 21

    SPARC Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of SDN-037 for the Treatment of Inflammation and Pain Associated with Ocular Surgery

    SPARC Licenses Commercialization Rights of ElepsiaTM XR to Tripoint Therapeutics

    SPARC to Provide Update on R&D Pipeline

    SPARC enters into a worldwide license agreement for SCD-044 with Sun Pharma

    SPARC to Provide Update on TaclantisTM NDA

  • 2019 - 20

    SPARC acquires Bioprojet’s rights for SCD-044

    SPARC Provides Update on Paclitaxel Injection Concentrate for Suspension (PICS) Litigation

    SPARC Enters into a Licensing Deal with CMS

    SPARC to Provide Update on R&D Pipeline

    SPARC Receives Orphan Drug Designation from the USFDA for SCO-088 for the Treatment of Patients with Chronic Myeloid Leukemia

    SPARC Announces U.S. FDA Acceptance of NDA for TaclantisTM (Paclitaxel Injection Concentrate for Suspension) for Filing and Regulatory Review

    HitGen and SPARC Enter DNA-Encoded Library Based Innovative Drug Discovery Research Collaboration

  • 2018 - 19

    Schrödinger and SPARC Announce Collaboration to Accelerate Neurodegeneration Drug Development Program

    SPARC Announces Top-line Results of Pivotal Bioequivalence Study for Paclitaxel Injection Concentrate for Suspension

    Sun Pharma and SPARC Announce US FDA Approval of XELPROS™ to Treat Open-angle Glaucoma or Ocular Hypertension

    Audio playback of Investors Presentation

    Update on R&D Pipeline

  • 2017 - 18

    SPARC Provides Update on Pivotal Phase III Studies of Baclofen GRS for Treatment of Spasticity in Patients with Multiple Sclerosis

    SPARC Announces Top-line Results of Pivotal Peak Inspiratory Flow (PIF) study and Low Dose Pharmacokinetic (PK) Study for Salmeterol – Fluticasone Dry Powder Inhaler (SPARC DPI)

  • 2016 - 17

    Announcement – Receipt of reclassification approval from BSE

    Announcement – Receipt of reclassification approval from NSE

    Update on NCE and NDDS Programs

    SPARC Licenses ELEPSIATM XR (Levetiracetam ER Tablets) to Sun Pharma

  • 2015 - 16

    Update on XELP ROST and Elepsia XRT

    SPARC Receives Complete Response Letter (CRL) from USFDA for Levetiracetam NDA

    SPARC Receives Complete Response Letter (CRL) from USFDA for Latanoprost NDA

    SPARC Licenses Xelpros™ to Sun Pharma

    SPARC receives USFDA approval for ELEPSIA XR

  • 2014 -15

    SPARC receives Complete Response Letter (CRL) from USFDA for Latanoprost NDA

    India Approval for Paclitaxel Injection Concentrate for Nanodispersion (PICN)

Copyright @ 2024. All Rights Reserved.
Follow Us :